METH1 polynucleotides
US7220557B2 · kind B2 · utility
5Cited by
6References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 13, 1999 |
| Grant date | May 22, 2007 |
| Priority date | — |
| Expiry date | Aug 13, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/026
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.